SK Plasma, an SK Group company specializing in blood products, announced on Sep. 1 that it has signed a three-party MOU with state-owned Indonesian pharmaceutical company Bio Pharma and the Indonesian Red Cross for production of blood plasma for Indonesia and technology transfer to its Indonesian partner.
This marked the first time that a Korean blood product company signed a contract to export technology to Indonesia. SK Plasma is Korea's only blood product producer which was spun off from SK Chemicals in 2015.
Under the MOU, SK Plasma will register its finished blood products in Indonesia and export them to Indonesia, produce Indonesian blood plasma at its plant in Andong, Korea, and transfer SK Plasma’s technology to Bio Pharma.
Blood products are nationally essential drugs used to treat inherent immunodeficiency diseases, hemophilia, and burns. However, due to high technological barriers to R&D and production and difficulties in securing stable raw materials from blood of healthy people, there are only about 30 blood product producers worldwide.